Malignant glioma: Who benefits from adjuvant chemotherapy?

Lisa M. DeAngelis, Peter C. Burger, Sylvan B. Green, J. Gregory Cairncross

Research output: Contribution to journalArticle

Abstract

We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

Original languageEnglish (US)
Pages (from-to)691-695
Number of pages5
JournalAnnals of Neurology
Volume44
Issue number4
DOIs
StatePublished - Oct 1998

Fingerprint

Adjuvant Chemotherapy
Glioma
Survival
Oligodendroglioma
Brain Neoplasms
Survivors
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

DeAngelis, L. M., Burger, P. C., Green, S. B., & Cairncross, J. G. (1998). Malignant glioma: Who benefits from adjuvant chemotherapy? Annals of Neurology, 44(4), 691-695. https://doi.org/10.1002/ana.410440418

Malignant glioma : Who benefits from adjuvant chemotherapy? / DeAngelis, Lisa M.; Burger, Peter C.; Green, Sylvan B.; Cairncross, J. Gregory.

In: Annals of Neurology, Vol. 44, No. 4, 10.1998, p. 691-695.

Research output: Contribution to journalArticle

DeAngelis, LM, Burger, PC, Green, SB & Cairncross, JG 1998, 'Malignant glioma: Who benefits from adjuvant chemotherapy?', Annals of Neurology, vol. 44, no. 4, pp. 691-695. https://doi.org/10.1002/ana.410440418
DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: Who benefits from adjuvant chemotherapy? Annals of Neurology. 1998 Oct;44(4):691-695. https://doi.org/10.1002/ana.410440418
DeAngelis, Lisa M. ; Burger, Peter C. ; Green, Sylvan B. ; Cairncross, J. Gregory. / Malignant glioma : Who benefits from adjuvant chemotherapy?. In: Annals of Neurology. 1998 ; Vol. 44, No. 4. pp. 691-695.
@article{6fb08c5cf6f14b2fb2d428036f81b58d,
title = "Malignant glioma: Who benefits from adjuvant chemotherapy?",
abstract = "We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.",
author = "DeAngelis, {Lisa M.} and Burger, {Peter C.} and Green, {Sylvan B.} and Cairncross, {J. Gregory}",
year = "1998",
month = "10",
doi = "10.1002/ana.410440418",
language = "English (US)",
volume = "44",
pages = "691--695",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Malignant glioma

T2 - Who benefits from adjuvant chemotherapy?

AU - DeAngelis, Lisa M.

AU - Burger, Peter C.

AU - Green, Sylvan B.

AU - Cairncross, J. Gregory

PY - 1998/10

Y1 - 1998/10

N2 - We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

AB - We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

UR - http://www.scopus.com/inward/record.url?scp=0031755577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031755577&partnerID=8YFLogxK

U2 - 10.1002/ana.410440418

DO - 10.1002/ana.410440418

M3 - Article

C2 - 9778271

AN - SCOPUS:0031755577

VL - 44

SP - 691

EP - 695

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -